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As our patient had no previous history of MS, it was 
difficult to differentiate it from other varieties of 
malignant demyelinating diseases especially ADEM. 
However, historical data, CSF analysis and radiographic 
characteristics of lesions suggested fulminant MS 
(table 2) (20). Radiological images were almost diagnostic 
of tumefactive demyelinating process based on size 
(2cm or more), location (periventricular and juxtacortical) 
and nature of lesions (confluent areas, mixed T2 
weighted iso and hyperintensity of enhanced regions, 
absence of cortical involvement and absence of a mass 
effect) (14,15,21,22) The lesions can be multifocal (83%) 
(as in our case) or unifocal (17%)(13) CSF analysis in our 
patient revealed absence of pleocytosis with elevated 
protein and presence of oligoclonal bands which is 
present in 11% to 33% of tumefactive MS cases,(13) 
favouring our diagnosis of tumefactive MS over ADEM. (23) 
Biopsy of the lesions is not routinely recommended to 
make a histological diagnosis. Standard treatment 
approach for fulminant MS variants is similar to severe 
relapses of MS. However, due to the rarity and high 
mortality associated with Marburg variant of MS, only a 
limited number of case reports  have shown some 
promising results for Plasma exchange and Mitoxantrone 
as treatment for acute phase and prevention of further 
relapses (4,5,24) There is one published study of 
Fulminant MS from Pakistan also from our centre where 
patients were treated with IV immunoglobulins followed 
by Mitoxantrone, with good outcomes(22).
Fig 4.  Follow up of patient in neurology clinic 3 months 
later.
We used Plasma exchange (PLEX) in this patient due to 
financial constraints. Mitoxantrone is an immun- 
omodulatory agent used as a disease modifying drug 
(DMD) to improve neurological disability and delay 
progression in relapsing remitting MS and secondary 
progressive MS (21). Several randomized clinical trials 
used 12mg/m2 dose administered once every 3 
months (21). We have previously used mitoxantrone for 
management of relapsing remitting MS (23) and as a 
DMD for Fulminant MS.22 Though FMS is a disease of 
severe morbidity and high mortality but better outcome 
can be expected if treated promptly and aggressively 
with disease modifying therapies early in the course of 
the disease.
CONCLUSION
Due to limitation of resources in our country, PLEX 
followed by Mitoxantrone may be a valuable option for 
treatment of fulminant multiple sclerosis.
REFERENCES
1.   Ropper A.H, Samuels, M.A. Adams and Victor’s 
     Principles of Neurology. 9th ed. USA: McGraw-Hill 
     Companies, Inc;2009. Chapter 36,page 875,885.
2.   Harper CG. Acute central nervous system disorder 
     mimicking stroke. Med J Austral 1981;1:136-8.
3.   Mendez MF, Pogacar S. Malignant monophasic 
     multiplesclerosOvis or "Marburg's disease".  Neurology, 
     1988;38:1153-5.
4.   Jeffery DR1, Lefkowitz DS, Crittenden JP. Treatment 
     of Marburg variant multiple sclerosis with 
     mitoxantrone. J Neuroimaging. 2004 Jan;14(1): 58-62.
5.   Le Page E1, Leray E, Taurin G, Coustans M, Chaperon 
     J, Morrissey SP, Edan G. Mitoxantrone as induction 
     treatment in aggressive relapsing remitting multiple 
     sclerosis: treatment response factors in a 5 year 
     follow-up observational study of 100 consecutive 
     patients. J Neurol Neurosurg Psychiatry. 2008 Jan; 
     79(1):52-6. Epub 2007 Sep 10.
6.   Scott LJ1, Figgitt DP. Mitoxantrone: a review of its 
     use in multiple sclerosis. CNS Drugs. 2004;18(6): 
     379-96.
7.   Ismail A. Khatri, Nadia Mehboob, Arsalan Ahmad, 
     Maimoona Siddiqui, Nauman S. Siddiqui. Use of 
     Mitoxantrone in MS – local experience at Shifa 
     International Hospital, Islamabad, Pakistan. Pak J 
     Neurol Sci 2012; 7(1):1-4. 
8.   Arsalan Ahmad, Nadia Mehboob, Ismail Abdul Latif 
     Khatri, Maimoona Siddiqui, Javeria Khizar, Maryam 
     Jameel. Fulminant variants of multiple sclerosis – 
     local experience at Shifa International Hospital, 
     Islamabad, Pakistan. RMJ. 2013; 38(1): 26-31.
9.   Nozaki K1, Abou-Fayssal N. High dose cyclophos-
     phamide treatment in Marburg variant multiple 
     sclerosis A case report. J Neurol Sci. 2010 Sep 
     15;296(1-2):121-3. doi: 10.1016/j.jns.2010.05.022. 
     Epub 2010 Jun 25.
10. Wattamwar PR, Baheti NN, Kesavadas C, Nair M, 
     Radhakrishnan A. Evolution and long term outcome 
     in patients presenting with large demyelinating 
     lesions as their first clinical event. J Neurol Sci. 
     2010 Oct 15; 297(1-2):29-35.
11. Lucchinetti CF1, Parisi J, Bruck W. The pathology of 
     multiple sclerosis. Neurol Clin. 2005 Feb;23(1): 
     77-105.
12. Masdeu JC1, Quinto C, Olivera C, Tenner M, Leslie 
     D, Visintainer P. Open-ring imaging sign: highly 
     specific for atypical brain demyelination. Neurology. 
     2000 Apr 11; 54(7): 1427-33.
13. Lucchinetti CF1, Gavrilova RH, Metz I, Parisi JE, 
     Scheithauer BW, Weigand S, Thomsen K, Man- 
     drekar J, Altintas A, Erickson BJ, König F, Giannini 
     C, Lassmann H, Linbo L, Pittock SJ, Brück W. 
     Clinical and radiographic spectrum of pathologically 
     confirmed tumefactive multiple sclerosis. Brain. 
     2008 Jul;131(Pt 7):1759-75.doi: 10.1093/brain 
     /awn098. Epub 2008 Jun 5.
14. Geeta A Khwaja*, Rajeev Ranjan**, Meena 
     Gupta***, Debashish Chowdhury*, Om Prakash** 
     Diagnostic Challenge and Pitfalls of3 Tumefactive 
     Multiple Sclerosis. JIACM 2010; 11(1): 72-77.
15. Megan R. Rahmlow, MD1 and Orhun Kantarci, MD 
     1 Fulminant Demyelinating Diseases. Neurohospitalist. 
     Apr 2013; 3(2): 81–91. 
16. Walid MS, Sanoufa M. The diagnosis of Marburg 
     Disease is course-dependent. GMS Ger Med Sci. 
     2010;8:Doc06.
17. Pittock SJ, Lucchinetti CF. The pathology of MS. 
     New insights and potential clinical applications. The 
     Neurologist 2007; 13: 45-56.
18. Guillain B, Alajouanine T. La forme aigue de la sclerose 
     en plaques. Bul Acad Med (Paris) 1928;99:366-76.
19. Banerjee AK, Chopra JS, Kunar BR. Acute multiple 
     sclerosis: report of a case with neuropathological 
     and neurochemical studies. Neurol India 1977; 
     25:233 -7.
20. Zahra T, Khan Z, Khan E.A, Ahmad A. Acute 
     disseminated encephalomyelitis (ADEM) presenting 
     as a multiphasic encephalopathy: A case report. Pak 
     J Neurol Sci 2013;8(4): 31-34
21. Dagher AP, Smirniotopoulos J. Tumefactive 
     demyelinating lesions. Neuroradiology. 1996; 38: 
     560–5.
22. Kim DS, et al. Distinguishing tumefactive 
     demyelinating lesions from glioma or central 
     nervous system lymphoma: Added value of 
     unenhanced CT compared with conventional 
     contrast-enhanced MR imaging. Radiology. 2009; 
     251:467-75.
23. De Seze J, Debouverie M, Zephir H, et al. Acute 
     fulminant demyelinating disease: a descriptive 
     study of 60 patients. Arch Neurol. 2007;64(10): 
     1426–1432.
24. Nozaki K1, Abou-Fayssal N. High dose cyclophosp- 
     hamide treatment in Marburg variant multiple 
     sclerosis A case report. J Neurol Sci. 2010 Sep 
     15;296(1-2):121-3. doi: 10.1016/j.jns.2010.0 
     5.022. Epub 2010 Jun 25.
came to be negative for malignancy. ANA was not done.
Patient showed gradual improvement in his clinical 
status and was discharged home 12 days later. He was 
given IV Mitoxantrone (12mg/m2), first dose given on 12 
day post admission and then once every 3 months. 
On discharge, EDSS improved from 9 to 5. He was 
followed in neurology clinic 3 months later with repeat 
MR imaging which showed interval regression in the size 
of previously noted lesions with no new activity (Fig.3). 
He showed remarkable clinical improvement, walking 
without support (EDSS 2) (Fig.4). He had no further 
relapse at 3 months.
DISCUSSION
Multiple sclerosis is the most common, idiopathic, 
inflammatory demyelinating disease of central nervous
system with a relapsing and remitting course (1)
Approximately 7% of patients may present with a 
fulminant disease (10). Tumefactive multiple sclerosis 
refers to large demyelinating lesions, typically 2 cm or 
larger in size, with surrounding mass effect, perilesional 
edema and open ring enhancement on gadolinium 
contrast (11,12,13). 
Figure 1. Axial diffusion weighted images(DWI) of Brain
(A) and (C) showing multiple nodular lesions of diffusion
restriction in bilateral parietal periventricular and 
subcortical regions, corresponding ADC images (B) 
and pons (D), largest one measuring 2.7×1.4 cm2.
They are iso-intense/hypointense on T1 (E) with subtle 
peripheral contrast enhancement (F) and correspondingly 
bright on FLAIR image with surrounding halo (G) and no 
significant mass effect.
First described nearly a century ago, Marburg variant of 
MS is a rare, acute, monophasic and highly aggressive 
form of MS, leading to severe morbidity or mortality 
within a few weeks to months.1 Due to its atypical 
clinical and radiographic features, it poses significant 
diagnostic dilemma (14). It presents with a polysymptomatic, 
monophasic illness (15) suggesting diffuse and extensive 
CNS involvement. 
Figure 2. Follow up MR images obtained 10 days later 
with new onset right hemiparesis and acute confusional 
state. DWI (A and C), ADC (B and D)and axial FLAIR 
images(E) showing development of new lesions and 
interval increase in size of previously observed multiple  
lesions which have become more confluent bilaterally.
Unlike classical MS, lesions occur simultaneously in all 
affected areas with large zones of confluent 
demyelination,(1,16) including cerebral hemisp- heres 
and brainstem (17) High mortality is associated with this 
variant especially with involvement of brainstem 
structures, (12,18,19) necessitating intensive care for 
aggressive management (15).First presentation of an 
acute, fulminant demyelinating event is the most 
common presentation in the course of tumefactive 
MS,13 hence early and prompt recognition of disease 
process and exclusion of infective, neoplastic, vasculitic and 
granulomatous disorder is of paramount importance.
Figure 3. Follow up MR images of same patient 
obtained at 3 months after resolution of acute neurological 
dysfunction. Axial T1 pre (A), post contrast (B) and FLAIR 
(C) images showing regression in size of previously noted 
lesions with no abnormal post contrast enhancement.
A RARE CASE OF SIMPLE HEREDITARY RECESSIVE OPTIC ATROPHY
ABSTRACT
Simple Autosomal Recessive Optic Atrophy (AROA) is a rare hereditary disorder that belongs to a group of disorders called 
Hereditary Optic Atrophy. Patients diagnosed with simple AROA have complete blindness since birth or from first few 
months of life. This blindness does not improve with age. However, no other organ or system is affected in this disorder. 
There is no known cause or gene mutation associated with it. Here we report a case of a two year old child diagnosed 
with simple AROA. Family history of the patient revealed that an older deceased relative also suffered from similar 
symptoms. Identification of this and similar cases of the simple AROA can help us better understand this disorder and 
hopefully one day help us develop a treatment for it.
INTRODUCTION
Hereditary optic atrophy (HOA) are a group of disorders 
that present with optic atrophy as an isolated symptom 
or along with complex multi-systemic disorders (1, 2). 
HOA includes: 1) simple Autosomal Recessive Optic 
Atrophy (AROA), 2) Autosomal Dominant Optic Atrophy, 
3) Behr’s syndrome and 4) Leber’s hereditary optic 
neuropathy. Optic atrophy is also a symptom of other 
disorders for example Friedreich's ataxia and Wolfram 
syndrome etc (1). The most frequent and well-known 
HOA disorders are the autosomal-dominant optic 
atrophy and Leber’s hereditary optic neuropathy  (3). In 
a typical case of simple AROA, blindness is present at 
birth, with associated pale optic disk and cupping,
proliferation of astrocytes, decreased retinal vasculature 
and occasionally pendularnystagmus (2, 4). One study 
mapped the disease-causing gene to chromosome 
8q21-q22; however no particular gene or mutation 
could be associated with disorder (5). In another study, 
mutation in the TMEM126A gene was associated with 
AROA (6, 7). Although severe visual loss manifest in early 
childhood in these patients, sensory-motor axonal 
neuropathy and sensorineural hearing defects also 
occurred in some cases, making the findings of this 
study possibly not relevant to simple AROA (6). Here we 
report a rare case of simple AROA, who has clinical 
features and family history suggestive of simple AROA.
CASE REPORT
A two year old patient presented in Pediatric Neurology 
clinic of Aga Khan University Hospital in September 
2014, with complaint of congenital blindness. The 
parents first noticed the symptoms when the child was 
three to four months old. The child did not follow the 
finger or blinked when exposed to light. Hearing and 
speech development was normal. The child’s interaction 
with other children and family members was normal, 
indicating normal intellectual development. The child 
resulted from a normal conception. Normal delivery 
occurred after nine months of uneventful-pregnancy. The 
child did not have any major trauma during development.
Figure 1. A detailed pedigree of a child diagnosed with 
autosomal recessive optic atrophy. The great grand-
uncle of the affected child was the only other individual 
diagnosed with simple AROA.
There was also no history of seizures, meningitis, 
encephalitis or any other neuro-developmental disorders. 
A detailed family history revealed that the child’s parents 
have a consanguineous marriage. The child’s great 
grand-uncle also had congenital blindness, similar to this 
child. The great grand-uncle was also normal in every 
other way and died at the age of 50 years. 
Figure 2. MRI of the transverse section of the brain. 
The thickness of both right and left optic nerve was 
0.9mm, while the optic chiasm measures 2.4mm. 
These values are significantly less than those observed 
in normally developing children of this age.
A detailed pedigree of this child is shown in figure 1. At 
the time of presentation in clinic the child’s general and 
detailed neurological examination were unremarkable, 
except for complete visual loss. A detailed ophthalmological 
exam revealed bilateral pale optic disk with indications of 
cupping and severe thinning of retinal vasculature. 
Magnetic Resonance Imaging of the child’s brain showed 
significant thinning of the optic nerves and chiasm 
(figure 2). After careful consideration of all the clinical, 
radiological and laboratory parameters the patient was 
diagnosed as a case of simple AROA.
DISCUSSION
Compared to Autosomal Dominant Optic Atrophy, Behr’s 
syndrome and Leber’s hereditary optic neuropathy, the 
simple AROA is a very rare disorder with no known cause 
or treatment options. In a study published over a decade 
ago, the mutation for simple AROA was mapped to 
chromosome 8q (5). Another study found an association 
between mutation in TMEM126A gene and simple AROA 
(7). However, some of the patients carrying mutationin 
TMEM126A gene were also reported to have 
sensory-motor axonal neuropathy and sensorineural 
hearing defects, making the diagnosis of simple AROA 
unlikely (6). Therefore, it is fair to conclude that the 
mutation for simple AROA remains undiscovered. Here 
we report a case of a two year old child diagnosed with 
simple AROA independently by a neurologist and an 
ophthalmologist. The identification of more such cases 
can be very helpful in improving our understanding of this 
disease and help us develop better diagnostic 
techniques and treatment strategies.
CONCLUSION
We have reported a rare case of simple AROA diagnosed 
in a two year old child with a family history also sugges-
tive of this diagnosis. Identification of similar cases can 
help us develop a better understanding of this disease 
and possibly help in developing a treatment strategy.  
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As our patient had no previous history of MS, it was 
difficult to differentiate it from other varieties of 
malignant demyelinating diseases especially ADEM. 
However, historical data, CSF analysis and radiographic 
characteristics of lesions suggested fulminant MS 
(table 2) (20). Radiological images were almost diagnostic 
of tumefactive demyelinating process based on size 
(2cm or more), location (periventricular and juxtacortical) 
and nature of lesions (confluent areas, mixed T2 
weighted iso and hyperintensity of enhanced regions, 
absence of cortical involvement and absence of a mass 
effect) (14,15,21,22) The lesions can be multifocal (83%) 
(as in our case) or unifocal (17%)(13) CSF analysis in our 
patient revealed absence of pleocytosis with elevated 
protein and presence of oligoclonal bands which is 
present in 11% to 33% of tumefactive MS cases,(13) 
favouring our diagnosis of tumefactive MS over ADEM. (23) 
Biopsy of the lesions is not routinely recommended to 
make a histological diagnosis. Standard treatment 
approach for fulminant MS variants is similar to severe 
relapses of MS. However, due to the rarity and high 
mortality associated with Marburg variant of MS, only a 
limited number of case reports  have shown some 
promising results for Plasma exchange and Mitoxantrone 
as treatment for acute phase and prevention of further 
relapses (4,5,24) There is one published study of 
Fulminant MS from Pakistan also from our centre where 
patients were treated with IV immunoglobulins followed 
by Mitoxantrone, with good outcomes(22).
Fig 4.  Follow up of patient in neurology clinic 3 months 
later.
We used Plasma exchange (PLEX) in this patient due to 
financial constraints. Mitoxantrone is an immun- 
omodulatory agent used as a disease modifying drug 
(DMD) to improve neurological disability and delay 
progression in relapsing remitting MS and secondary 
progressive MS (21). Several randomized clinical trials 
used 12mg/m2 dose administered once every 3 
months (21). We have previously used mitoxantrone for 
management of relapsing remitting MS (23) and as a 
DMD for Fulminant MS.22 Though FMS is a disease of 
severe morbidity and high mortality but better outcome 
can be expected if treated promptly and aggressively 
with disease modifying therapies early in the course of 
the disease.
CONCLUSION
Due to limitation of resources in our country, PLEX 
followed by Mitoxantrone may be a valuable option for 
treatment of fulminant multiple sclerosis.
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came to be negative for malignancy. ANA was not done.
Patient showed gradual improvement in his clinical 
status and was discharged home 12 days later. He was 
given IV Mitoxantrone (12mg/m2), first dose given on 12 
day post admission and then once every 3 months. 
On discharge, EDSS improved from 9 to 5. He was 
followed in neurology clinic 3 months later with repeat 
MR imaging which showed interval regression in the size 
of previously noted lesions with no new activity (Fig.3). 
He showed remarkable clinical improvement, walking 
without support (EDSS 2) (Fig.4). He had no further 
relapse at 3 months.
DISCUSSION
Multiple sclerosis is the most common, idiopathic, 
inflammatory demyelinating disease of central nervous
system with a relapsing and remitting course (1)
Approximately 7% of patients may present with a 
fulminant disease (10). Tumefactive multiple sclerosis 
refers to large demyelinating lesions, typically 2 cm or 
larger in size, with surrounding mass effect, perilesional 
edema and open ring enhancement on gadolinium 
contrast (11,12,13). 
Figure 1. Axial diffusion weighted images(DWI) of Brain
(A) and (C) showing multiple nodular lesions of diffusion
restriction in bilateral parietal periventricular and 
subcortical regions, corresponding ADC images (B) 
and pons (D), largest one measuring 2.7×1.4 cm2.
They are iso-intense/hypointense on T1 (E) with subtle 
peripheral contrast enhancement (F) and correspondingly 
bright on FLAIR image with surrounding halo (G) and no 
significant mass effect.
First described nearly a century ago, Marburg variant of 
MS is a rare, acute, monophasic and highly aggressive 
form of MS, leading to severe morbidity or mortality 
within a few weeks to months.1 Due to its atypical 
clinical and radiographic features, it poses significant 
diagnostic dilemma (14). It presents with a polysymptomatic, 
monophasic illness (15) suggesting diffuse and extensive 
CNS involvement. 
Figure 2. Follow up MR images obtained 10 days later 
with new onset right hemiparesis and acute confusional 
state. DWI (A and C), ADC (B and D)and axial FLAIR 
images(E) showing development of new lesions and 
interval increase in size of previously observed multiple  
lesions which have become more confluent bilaterally.
Unlike classical MS, lesions occur simultaneously in all 
affected areas with large zones of confluent 
demyelination,(1,16) including cerebral hemisp- heres 
and brainstem (17) High mortality is associated with this 
variant especially with involvement of brainstem 
structures, (12,18,19) necessitating intensive care for 
aggressive management (15).First presentation of an 
acute, fulminant demyelinating event is the most 
common presentation in the course of tumefactive 
MS,13 hence early and prompt recognition of disease 
process and exclusion of infective, neoplastic, vasculitic and 
granulomatous disorder is of paramount importance.
Figure 3. Follow up MR images of same patient 
obtained at 3 months after resolution of acute neurological 
dysfunction. Axial T1 pre (A), post contrast (B) and FLAIR 
(C) images showing regression in size of previously noted 
lesions with no abnormal post contrast enhancement.
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INTRODUCTION
Hereditary optic atrophy (HOA) are a group of disorders 
that present with optic atrophy as an isolated symptom 
or along with complex multi-systemic disorders (1, 2). 
HOA includes: 1) simple Autosomal Recessive Optic 
Atrophy (AROA), 2) Autosomal Dominant Optic Atrophy, 
3) Behr’s syndrome and 4) Leber’s hereditary optic 
neuropathy. Optic atrophy is also a symptom of other 
disorders for example Friedreich's ataxia and Wolfram 
syndrome etc (1). The most frequent and well-known 
HOA disorders are the autosomal-dominant optic 
atrophy and Leber’s hereditary optic neuropathy  (3). In 
a typical case of simple AROA, blindness is present at 
birth, with associated pale optic disk and cupping,
proliferation of astrocytes, decreased retinal vasculature 
and occasionally pendularnystagmus (2, 4). One study 
mapped the disease-causing gene to chromosome 
8q21-q22; however no particular gene or mutation 
could be associated with disorder (5). In another study, 
mutation in the TMEM126A gene was associated with 
AROA (6, 7). Although severe visual loss manifest in early 
childhood in these patients, sensory-motor axonal 
neuropathy and sensorineural hearing defects also 
occurred in some cases, making the findings of this 
study possibly not relevant to simple AROA (6). Here we 
report a rare case of simple AROA, who has clinical 
features and family history suggestive of simple AROA.
CASE REPORT
A two year old patient presented in Pediatric Neurology 
clinic of Aga Khan University Hospital in September 
2014, with complaint of congenital blindness. The 
parents first noticed the symptoms when the child was 
three to four months old. The child did not follow the 
finger or blinked when exposed to light. Hearing and 
speech development was normal. The child’s interaction 
with other children and family members was normal, 
indicating normal intellectual development. The child 
resulted from a normal conception. Normal delivery 
occurred after nine months of uneventful-pregnancy. The 
child did not have any major trauma during development.
Figure 1. A detailed pedigree of a child diagnosed with 
autosomal recessive optic atrophy. The great grand-
uncle of the affected child was the only other individual 
diagnosed with simple AROA.
There was also no history of seizures, meningitis, 
encephalitis or any other neuro-developmental disorders. 
A detailed family history revealed that the child’s parents 
have a consanguineous marriage. The child’s great 
grand-uncle also had congenital blindness, similar to this 
child. The great grand-uncle was also normal in every 
other way and died at the age of 50 years. 
Figure 2. MRI of the transverse section of the brain. 
The thickness of both right and left optic nerve was 
0.9mm, while the optic chiasm measures 2.4mm. 
These values are significantly less than those observed 
in normally developing children of this age.
A detailed pedigree of this child is shown in figure 1. At 
the time of presentation in clinic the child’s general and 
detailed neurological examination were unremarkable, 
except for complete visual loss. A detailed ophthalmological 
exam revealed bilateral pale optic disk with indications of 
cupping and severe thinning of retinal vasculature. 
Magnetic Resonance Imaging of the child’s brain showed 
significant thinning of the optic nerves and chiasm 
(figure 2). After careful consideration of all the clinical, 
radiological and laboratory parameters the patient was 
diagnosed as a case of simple AROA.
DISCUSSION
Compared to Autosomal Dominant Optic Atrophy, Behr’s 
syndrome and Leber’s hereditary optic neuropathy, the 
simple AROA is a very rare disorder with no known cause 
or treatment options. In a study published over a decade 
ago, the mutation for simple AROA was mapped to 
chromosome 8q (5). Another study found an association 
between mutation in TMEM126A gene and simple AROA 
(7). However, some of the patients carrying mutationin 
TMEM126A gene were also reported to have 
sensory-motor axonal neuropathy and sensorineural 
hearing defects, making the diagnosis of simple AROA 
unlikely (6). Therefore, it is fair to conclude that the 
mutation for simple AROA remains undiscovered. Here 
we report a case of a two year old child diagnosed with 
simple AROA independently by a neurologist and an 
ophthalmologist. The identification of more such cases 
can be very helpful in improving our understanding of this 
disease and help us develop better diagnostic 
techniques and treatment strategies.
CONCLUSION
We have reported a rare case of simple AROA diagnosed 
in a two year old child with a family history also sugges-
tive of this diagnosis. Identification of similar cases can 
help us develop a better understanding of this disease 
and possibly help in developing a treatment strategy.  
ACKNOWLEDGEMENTS
We would like to thank Dr. HR Ahmad for his support 
and guidance during this study.
REFERENCES
1.   La Morgia C, Carbonelli M, Barboni P, Sadun AA, 
     Carelli V. Medical management of hereditary optic 
     neuropathies. Front Neurol. 2014; 5:141.
2.   Yanoff M, Sassani JW. Optic Nerve. In: Yanoff M, 
     Sassani JW, editors. Ocular Pathology. Yanoff: 
     Sassani; 2009. p. 497-527.Ocular Pathology 
     Sixth Edition. 2009.
3.   Neuhann T, Rautenstrauss B. Genetic and 
     phenotypic variability of optic neuropathies. Expert 
     Rev Neurother. 2013; 13: 357-67.
4.   Vaphiades M, Brodsky MC. Pediatric optic atrophy. 
     IntOphthalmolClin. 2012; 52: 17-28.
5.   Barbet F, Gerber S, Hakiki S, Perrault I, Hanein S, 
     Ducrog D, et.al. A first locus for isolated autosomal 
     recessive optic atrophy (ROA1) maps to chromosome 
     8q. Eur J Hum Genet. 2003; 11: 966-71.
6.   Meyer E, Michaelides M, TeeLJ, Robson AG, 
     Rahman F, Pasha S et.al. Nonsense mutation in 
     TMEM 126 A causing autosomal recessive optica 
     trophy and auditory neuropathy. Mol Vis. 2010; 
     16: 650-64. 
7.   Hanein S, Perrault I, Roche O, Gerber S, Khandom 
     N, Rio M et.al. TMEM126A, encoding a 
     mitochondrial protein, is mutated in autosomal- 
     recessive nonsyndromic optic atrophy. Am J Hum 
     Genet. 2009; 84: 493-8.
3 5 V O L .  1 0  ( 2 )  A P R   -   J U N   2 0 1 5P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S
